ClinicalTrials.gg
TerminatedNCT05153330Updated Jul 3, 2025

Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL

A Phase 1 interventional study of BMF-219 in Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Acute Mixed-Phenotype Leukemia, sponsored by Biomea Fusion Inc.. Terminated at 41 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-03.

Sponsored by Biomea Fusion Inc. · Phase 1, Interventional, and Treatment

Why this study was terminated
Biomea Fusion, Inc., is no longer pursuing oncology indications for BMF-219. No safety concerns or efficacy observations led to this study closure.

From the registry’s dates

  • Primary completion was Feb 2025, 1 year 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
55
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,137 studies in Leukemia, Myeloid, Acute with a site in United States — 312 open to participants now, 466 under way, 24 of them phase 3. Leukemia, Myeloid, Acute · United States.

Enrollment
598th of 1,907
55 · median 35
Started
2022
with 80 others
Phase 1
772 of 2,137
130 open now
Registered
1,818th of 2,137
by date

Among the 2,137 studies in Leukemia, Myeloid, Acute with a site in United States, this one is the 598th largest by enrollment of the 1,907 interventional ones that give a count, is one of 81 that started in 2022, is one of 772 in phase 1, and was the 1,818th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

312 of the 2,137 studies in Leukemia, Myeloid, Acute with a site in United States are open now. Recruiting first, the newest first:

307 more — sign in →

All 312 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,137 studies in Leukemia, Myeloid, Acute with a site in United States, or all of them as a file.
02

Study summary

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL.

Read the detailed description

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) with mixed lineage leukemia 1-rearranged (KMT2A/ MLL1r), nucleophosmin 1 (NPM1), diffuse large b-cell lymphoma (DLBCL), multiple myeloma (MM), and chronic lymphocytic lymphoma (CLL)/ small lymphocytic lymphoma (SLL).

03

Conditions studied

  • Acute Myeloid Leukemia
  • Acute Lymphoblastic Leukemia
  • Acute Mixed-Phenotype Leukemia
  • Cancer
  • Refractory
  • Progression
  • Diffuse Large B Cell Lymphoma
  • Multiple Myeloma
  • Lymphoma
  • Lymphoma, Non-Hodgkin
  • Myeloma, Plasma-Cell
  • Myelomatosis
  • Plasma Cell Myeloma
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years.
  • All subjects must have or pathologically confirmed diagnosis of their and/ or measurable R/ R disease, as follows:

    1. Cohort 1 only: or relapsed acute leukemia defined as > 5% blasts in the bone marrow or reappearance of blasts in the peripheral blood.
    2. Cohort 2 only: Previously treated, pathologically confirmed de novo DLBCL, or DLBCL transformed from previously indolent lymphoma (e.g., follicular lymphoma) with documented clinical or radiological evidence of progressive or persistent disease. At study entry, subjects must have as per the revised criteria for response assessment of lymphoma.
    3. Cohort 3 only: Measurable MM.
    4. Cohort 4 only: Previously treated subjects with active CLL/SLL with meeting at least 1 of the iwCLL 2018 criteria for requiring treatment.
  • Subjects must be refractory or must have progressed on, or following discontinuation of the most recent anti-cancer therapy, with the following considerations:

    1. Cohort 1 only: Have failed or are ineligible for any approved standard of care therapies, including (Hematopoietic Stem Cell Transplantation).
    2. Cohort 2 only: Must have received at least 2 previous systemic regimens for the treatment of their de novo or transformed DLBCL.
    3. Cohort 3 only: Must have received at least 3 anti-MM regimens including proteasome inhibitor.
    4. Cohort 4 only: Must have received at least 2 prior systemic treatment regimens.
  • performance status of 0-2 and an estimated expected of > 3 months in the opinion of the Investigator.
  • Adequate organ function.
  • Both men and women of or their partners must use adequate measures during the course of the trial and for at least 90 days after discontinuing study treatment.

Exclusion criteria

Exclusion Criteria:

Subjects who meet any of the following criteria will not be enrolled in the study (all cohorts, unless otherwise indicated):

  • Certain disease subtypes or occurrences, as follows:

    1. Cohort 1: Acute promyelocytic leukemia (APL), chronic myeloid leukemia (CML) in blast crisis.
    2. Cohort 2: Primary mediastinal B-cell lymphoma (PMBCL), DLBCL transformed from diseases other than indolent non-Hodgkin's Lymphoma (NHL).
    3. Cohort 3: Active plasma cell leukemia, myeloma with amyloidosis, systemic light chain amyloidosis.
    4. Cohort 4: Known or suspected history of Richter's transformation.
  • White Blood Count (WBC) > 50,000/μL (uncontrollable with cytoreductive therapy) (Cohort 1 only).
  • Known central nervous involvement, as follows:

    1. Cohort 1: Clinically active central nervous system (CNS) leukemia. Previously controlled CNS leukemia is acceptable.
    2. Cohort 2: Active CNS lymphoma or meningeal involvement.
    3. Cohort 3: Active CNS MM.
    4. Cohort 4: Active CNS leukemia.
  • Prior menin inhibitor therapy.
  • Known positive test for , , or surface antigen.
  • Subjects with a pre-existing disorder predisposing them to a serious or life-threatening infection.
  • An active uncontrolled acute or chronic systemic fungal, bacterial, or viral infection.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Dose Escalation Phase

    Experimental: ARM A: Study participants who are not receiving a moderate or strong CYP3A4 inhibitor. Dose Escalation Phase: * Cohort 1: Participants with acute leukemia * Cohort 2: Participants with diffuse large B-cell lymphoma * Cohort 3: Participants with multiple myeloma * Cohort 4: Participants with chronic lymphocytic leukemia/ small lymphocytic lymphoma Participants will receive escalating dose BMF-219 orally once per day to identify the OBD/RP2D (Optimal Biologic Dose/Recommended Ph2 Dose). Dose Expansion Phase: Cohorts 1, 2, 3, and 4 will receive BMF-219 at the OBD/ RP2D to further assess the safety/ efficacy of the investigational drug.

    Drug: BMF-219

  • Experimental
    Dose Expansion

    Experimental: ARM B: Study participants who are receiving a moderate or strong CYP3A4 inhibitor. Dose Escalation Phase: • Cohort 1: Participants with acute leukemia will receive escalating dose BMF-219 orally to identify the OBD/ RP2D (Optimal Biologic Dose/Recommended Ph2 Dose). Dose Expansion Phase: Cohort 1 will receive BMF-219 at the OBD/ RP2D to further assess the safety and efficacy of the investigational drug.

    Drug: BMF-219

Interventions

  • BMF-219 is orally administered in continuous 28 day cycles. Alternative BID dosage may be used.

    Also known as: Covalent Menin Inhibitor

06

What researchers measure

Primary outcomes

  1. Determine Optimal Biologic Dose (OBD) and RP2D of BMF-219 monotherapy for (Cohorts 1, 2, 3 & 4)

    Determine Optimal Biologic Dose (OBD) and recommended Phase 2 dose (RP2D) of BMF-219 monotherapy in subjects with refractory or relapsed (R/ R) acute leukemia (Cohort 1), diffuse large B-cell lymphoma (Cohort 2), multiple myeloma (Cohort 3), and chronic lymphocytic leukemia/ small lymphocytic lymphoma (Cohort 4).

    Time frame: At the end of Cycle 1 (each Cycle is 28 Days in duration)

Secondary outcomes

  1. Evaluate the Safety treatment-emergent TEAEs and SAEs

    Evaluate the Safety of BMF-219 as expressed by treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs).

    Time frame: 28 Days after last dose.

07

Study locations

41 sites
  • University of California, Irvine
    Irvine, California 92697, United States
  • University of Southern California Norris Cancer Center
    Los Angeles, California 90033, United States
  • UCLA Department of Medicine
    Los Angeles, California 90095, United States
  • UC Davis Comprehensive Cancer Center
    Sacramento, California 95817, United States
  • Stanford Cancer Center
    Stanford, California 94305, United States
  • Mayo Clinic
    Jacksonville, Florida 32224, United States
  • Mount Sinai Medical Center
    Miami Beach, Florida 33140, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Blood & Marrow Transplant Group of GA (Northside Hospital)
    Atlanta, Georgia 30342, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • University of Cincinnati Medical Center
    Cincinnati, Ohio 45219, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Virginia Cancer Specialists
    Gainesville, Virginia 20155, United States
  • Evangelismos General Hospital of Athens
    Athens, 106 76, Greece
  • Alexandra General Hospital of Athens
    Athens, 115 28, Greece
  • AOU Ospedali Riuniti Ancona
    Ancona, 60126, Italy
  • ASST Papa Giovanni XXIII Hospital Bergamo
    Bergamo, 24128, Italy
  • Instituto Clinico Humanitas
    Milan, 20089, Italy
  • IRCCS Ospedale San Raffaele, Programma di Ricerca Strategica su LLC
    Milan, 20132, Italy
  • Istituto Europeo di Oncologia
    Milan, 435 - 20141, Italy
  • Ospedale Santa Maria della Misericordia
    Perugia, 06132, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Roma, 00168, Italy
  • Amsterdam UMC
    Amsterdam, 1081HV, Netherlands
  • UMCG Groningen
    Groningen, 9700 RB, Netherlands
  • Radboud University Medical Center
    Nijmegen, 6500 HB, Netherlands
  • Erasmus University Medical Center Rotterdam
    Rotterdam, 3015 GD, Netherlands
  • Hospital General de Albacete
    Albacete, 02006, Spain
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Institut Catala d'Oncologia
    Barcelona, 08916, Spain
  • Hospital San Pedro de Alcántara
    Cáceres, 10003, Spain
  • Hospital Universitario de la Princesa
    Madrid, 28006, Spain
  • Hospital Universitario Fundación Jiménez Díaz
    Madrid, 28040, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario Central de Asturias
    Oviedo, 33011, Spain
  • Hospital Universitario de Salamanca
    Salamanca, 37007, Spain
  • Hospital Universitario Virgen del Rocio
    Seville, 41013, Spain
  • Hospital Universitario y Politécnico La Fe
    Valencia, 46026, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2022 to primary completion in Feb 2025, 36 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2021
First posted
Dec 10, 2021
StartActual
Jan 24, 2022
Primary completionActual
Feb 13, 2025
CompletionActual
May 2, 2025
Last update
Jul 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05153330
Lead sponsor
Biomea Fusion Inc.
Responsible party
Sponsor
First posted
Dec 10, 2021
Start date
Jan 24, 2022
Primary completion
Feb 13, 2025
Completion
May 2, 2025
Last update
Jul 3, 2025

Study contacts

Steve Morris, MD
study director · Biomea Fusion Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Icovamenib

Start the discussion